Abstract  
Objective: To report vision-related symptoms and neuro-visual clinical signs in patients approximately 4 months after discharge from hospitalization after COVID-19 infection. To report on coexisting functional and activity limitations.  
Design: The study is part of an ambidirectional population-based cohort study.  
Setting: An outpatient setting in a hospital environment.  
Participants: Patients from a population-based cohort study including all patients with laboratory-confirmed COVID-19 admitted to hospital during a 3-month period in a health care region in Sweden. Among patients who, based on a standardized telephone interview, were identified as having persisting rehabilitation needs 4 months after discharge (n=185), several (n=57) reported vision-related symptoms. All 57 patients were invited to a neuro-visual examination. Six patients declined, 6 were unavailable, and 3 did not fulfill the inclusion criteria. Thus, 42 patients were included in the analysis (N=42).  
Interventions: Not applicable.  
Main Outcome Measures: Vision-related symptoms, neuro-visual function, and coexisting impairments affecting activities of daily life and participation.  
Results: A total of 31% of patients with rehabilitation needs after COVID-19 reported vision-related symptoms. Reading-related issues (73.8%), blurry vision (69.0%), and light sensitivity (66.7%) were the most common symptoms. Patients with reading-related issues showed a higher level of eye strain ($P<.001$). Neuro-visual deficits were found in 83.3% of the patients, mainly concerning eye teaming (23.1%-66.7%) and eye movement (28.6%-30.8%) functions. Patients...
The World Health Organization declared COVID-19 a pandemic in March 2020, and the virus has had, and likely will continue to have, a significant effect on the world’s population as well as on health care and socioeconomic structures. The virus has been described as a multisystem disease affecting different organs and body functions, often with prolonged consequences on the health and daily life of individuals. The central and peripheral nervous system may be affected, leading to a wide variety of neurologic manifestations. Because of the heterogeneity of the manifestations, different possible pathogenic pathways have been suggested, for example, direct neural invasion, immune-mediated processes, endothelial dysfunction, and hypercoagulability. The increasing number of studies reporting on a variety of symptoms persisting after COVID-19, particularly cognitive impairments, underscore the need for multiprofessional rehabilitation.

One commonly reported symptom that persists after COVID-19 is mental fatigue, often in combination with neurocognitive symptoms such as memory impairment, concentration difficulties, and/or an increased sensitivity to light and sound, all of which have an effect on a person’s ability to manage their daily life. However, symptoms related to visual dysfunction have rarely been examined and described in this context. Issues pertaining to visual function and its combination with mental fatigue have been described in patients with acquired brain injuries (ABIs). By analogy, visual function should potentially be considered in the review of patients’ rehabilitation needs after COVID-19. In addition, visual impairments have been found to affect the ability to benefit from rehabilitation and resume daily activities after ABI.

Ophthalmic (eye-related) manifestations associated with COVID-19 may occur as a presenting feature of the disease or may develop weeks after recovery. The prevalence is reported to be low, and they most commonly involve the anterior part of the eye, for example, dry eyes and conjunctivitis. In addition, inner parts of the eye may be involved, for example, retinal disease. Neuro-ophthalmic symptoms include headache, ocular pain, visual impairment, and double vision, and the signs may involve optic neuritis, visual disturbances due to encephalopathy or stroke, cranial nerve palsies, and eye movement disorders. In addition to healthy eyes, different neuro-visual skills are required for functional vision and performance of daily activities. In this context, we refer to the ability to comfortably maintain clear, stable, and flexible vision in daily activities, occupational tasks, and interaction with others. Basic visual functions enabling this include visual acuity, contrast vision, binocular (eye teaming) functions, and eye movements.

This study reports on persisting neuro-visual function issues and symptoms after discharge from hospitalization because of COVID-19 infection. A second aim was to report on coexisting functional and activity limitations as sequelae of the infection.

**Methods**

**Setting**

This study is part of the Linköping COVID-19 Study, an ambidirectional population-based cohort study that included all patients with laboratory-confirmed COVID-19 admitted to hospital during a 3-month period in one of 21 health care regions in Sweden. All survivors at 4 months after discharge were invited to participate in a structured telephone interview. A total of 433 patients participated (response rate 94%). As part of the Linköping COVID-19 Study, medical records were searched to classify the severity of COVID-19 at hospitalization according to the World Health Organization Clinical Progression Scale (CPS). Patients were classified as follows: CPS 4-5, hospitalized, moderate disease; CPS 6, hospitalized, severe disease, nonmechanically ventilated; and CPS 7-9, hospitalized severe disease.

**The telephone interview**

The interview followed a standardized protocol comprising 37 questions, including questions on persisting symptoms from COVID-19 on body function (n=25) as well as activity and/or participation (n=12), referring to the International Classification of Function, Disability, and Health. Patients were instructed to only report new or exacerbated symptoms in relation to COVID-19. For each reported symptom, the patient was asked to estimate the effect on everyday life on a scale from 1-5 (1, no effect; 2, to a minor degree; 3, to some degree; 4, to a high degree; 5, to a very high degree). Eight questions concerned vision-related symptoms (shown in table 1) and were selected based on symptoms commonly found in individuals undergoing rehabilitation because of ABI or disease.

About 40% of all interviewed patients were identified by the interviewers and confirmed with a rehabilitation team as having a need for further clinical assessments and potentially rehabilitation interventions, based primarily on to
what degree the symptoms affected daily life. Those participants were then invited to a clinical examination by a multi-professional rehabilitation team about 5 months after discharge from hospital (fig 1). Patients who reported neuro-visual symptoms with a significant effect on daily life (3-5 on the rating scale) at the time of the interview or at the clinical visit were offered a special neuro-visual assessment approximately 5-6 months after hospitalization. Non-Swedish-speaking patients were assisted by an interpreter both at the telephone interview and the neuro-visual examination.

**Neuro-visual examination**

The neuro-visual examination included a detailed self-reported assessment of vision-related symptoms, an in-depth vision examination, and an assessment of reading-related oculomotor skills.

Vision-related self-reported symptoms were assessed with the Vision Interview (VI) and the Convergence Insufficiency Symptom Survey (CISS). These documents were filled in by the patient before the vision examination. The VI is an 18-item structured questionnaire (questions shown in table 2) intended as support when reviewing visual impairments after ABI, including infection diagnoses. CISS consists of 15 questions concerning symptoms associated with reading and near activity graded on a Likert scale (0, never; 1, infrequently; 2, sometimes; 3, fairly often; 4, always). A total score of 21 or more is considered a high level of symptoms. Symptoms concerning light sensitivity and dizziness were assessed as part of the anamnesis using a selection of questions adapted from questionnaires in previous research.

The in-depth vision examination was performed by a licensed optometrist with neuro-rehabilitation experience. It included a brief anamnesis, visual acuity at near and far, eye motility, stereovision, eye teaming function, eye movement function, accommodation, and contrast vision (table 3). Eye motility and eye movement function were clinically examined using criteria adapted from the Ocular Motor Score. Exclusion criteria were premorbid eye disease and neurologic disorder causing severe visual impairment.

The Developmental Eye Movement Test was used to examine oculomotor skills in a simulated reading task. The patient reads out numbers arranged vertically and horizontally on 3 different test cards. The ratio between vertical and horizontal reading duration is then calculated.

**Statistical analysis**

The statistical analyses were done using SPSS Statistics 25 and/or Microsoft Excel 2010. Chi-square or Fisher exact test was used for analysis of cross-tabulations of frequencies. Welch’s t test or analysis of variance was used for comparing means. Normality tests were performed with the Kolmogorov-Smirnov method. A P value <.05 was set as the level of significance.

**Ethics**

The study adhered to the tenets of the Declaration of Helsinki and was approved by the Swedish Ethical Review Authority (Dnr 2020-03029 and 2020-04443). All patients gave informed consent before participation.

**Results**

Fifty-seven of the 185 patients invited to a clinical examination (31%) were also invited to a neuro-visual examination.
total of 42 patients attended the examination and were thus included in the analysis (table 4).

The validity of the selection process of patients invited to a neuro-visual assessment was reviewed retrospectively; the responses from those invited (n=57) were compared with those not invited (n=128) for 6 of the 8 telephone interview questions about visual symptoms (questions about headache and giddiness excluded). A chi-square test showed a significant association between group and symptoms, confirming that patients invited to the vision examination were much more likely to experience visual symptoms affecting their daily life (P<.01).

**Telephone interview responses by patients invited to the neuro-visual examination**

The number of patients who responded affirmatively to questions pertaining to visual dysfunction and rated the effect 3-5 (certain to high effect on daily life) are shown in table 1. A chi-square test showed no association between symptoms and CPS classification.

**Results from the neuro-visual examination**

**Visual symptoms according to the VI**

The most reported symptoms were reading difficulties, blurry vision, dazzled by light, and an increased need for light while reading (see table 2). Patients who had experienced a visual phenomenon described it as foggy vision (n=15) or in the form of flares, dots of light, or stars in their field of vision (n=13).

**Visual symptoms when reading and for near work according to CISS**

The mean CISS score was 25.9±10.6 for the total group, suggesting an increased level of symptoms (cut off score ≥21). There was no difference between the groups based on CPS classification. For patients experiencing reading-related difficulties according to the VI (n=31), the mean CISS score was 29.7±8.8 compared with 15.2±7.3 for patients without reading-related difficulties (P<.01).

**Headache**

In the anamnesis, 20 patients reported headaches of greater intensity or to occur more frequently after the infection. Six patients reported the headache to be specifically associated with reading and near activity according to CISS.

**Light sensitivity**

Twenty-three patients (54.8%) experienced moderate to severe discomfort when exposed to light and that vision was degraded when exposed to light. Common factors perceived to worsen the symptoms were fatigue, time (worsens as the day goes on), watching television, and the use of a computer, tablet, or mobile phone. All types of light, indoors as well as outdoors, could be bothersome. No association between symptoms and the CPS classification was found. There was no association between light sensitivity and headache.
### Table 2  Vision Interview

| No. | Item                                                                 | No. of Responses | Yes | No | Don’t Know |
|-----|----------------------------------------------------------------------|------------------|-----|----|------------|
| 1   | Have you noticed any type of vision change?                          | 42               | 32  | 6  | 4          |
| 2   | Do you experience double vision?                                     | 42               | 7   | 34 | 1          |
| 3   | Do you experience reading difficulties?                              | 42               | 31  | 11 | 0          |
| 4   | Do you experience difficulty when moving among people and objects?   | 42               | 4   | 32 | 6          |
| 5   | Do you frequently bump into people or objects?                       | 42               | 11  | 28 | 3          |
| 6   | Do you experience difficulty with depth perception, eg, on stairs?   | 42               | 11  | 28 | 3          |
| 7   | Do you experience difficulty with eye-hand coordination, eg, when reaching for a glass? | 42               | 4   | 38 | 0          |
| 8   | Do you experience difficulty recognizing faces?                     | 41               | 1   | 40 | 0          |
| 9   | Do you perceive familiar faces differently?                          | 42               | 6   | 33 | 3          |
| 10  | Do you become more dazzled by light?                                 | 42               | 28  | 10 | 4          |
| 11  | Do you need more light in general to see well?                       | 38               | 15  | 17 | 6          |
| 12  | Do you need more light while reading?                                | 40               | 23  | 12 | 5          |
| 13  | Is your vision blurrer now?                                          | 42               | 29  | 9  | 4          |
| 14  | Is your color perception different now?                              | 41               | 3   | 30 | 8          |
| 15  | Have you experienced any visual phenomenon?                          | 39               | 28  | 11 | 0          |
| 16  | Have you experienced any other visual concern?                       | 39               | 10  | 24 | 5          |
| 17  | Is your visual field affected?                                       | 39               | 5   | 27 | 7          |
| 18  | Have you had an eye or vision examination since the injury?          | 39               | 9   | 30 | 0          |

### Table 3  List of visual functions examined, assessment methods, and assessment criteria

| Visual function                          | Method                                | Criteria                                                                 |
|------------------------------------------|---------------------------------------|--------------------------------------------------------------------------|
| Visual acuity                            | Snellen Vision Chart at 3 m           | Monocular decimal acuity 1.0 or better                                   |
| Near visual acuity                       | Near vision chart at 40 cm            | Binocular acuity of 5 p or better with or without reading aids           |
| Eye motility                             | Clinical assessment (OMS)              | (A) No restrictions in 8 gaze directions                                |
|                                          |                                       | (B) Some form of motility restriction, over or under functions           |
|                                          |                                       | (C) Advanced motility restriction/apraxia                               |
| Stereovision                             | Lang II stereotest                    | Positive (identifies all symbols), negative (sees only star), partially  |
|                                          |                                       | positive (cannot identify the symbols)                                  |
| Binocular function                       | RAF near point ruler                  | Near point of convergence >10 cm                                        |
| Convergence facility                     | 3 base in 12 base out prism           | Age 39 y or younger, minimum 11 cycles/min                               |
|                                          |                                       | Age 40 y or older min 7 cycles/min                                      |
| Fusion vergences at distance, 3 m        | RAF near point ruler                  | Fusion vergence width <19 prism diopters                                |
| Fusion vergences at near, 40 cm          | RAF near point ruler                  | Fusion vergence width <27 prism diopters                                |
| Eye movements                            | Observation                           | (A) Stabile fixation in primary and 6 gaze directions                    |
|                                          |                                       | (B) Saccadic intrusions, detectable drifts                              |
|                                          |                                       | (C) Nystagmus observed                                                  |
| Pursuit movement                         | Observation                           | (A) No intruding saccades, no head movements                            |
|                                          |                                       | (B) 3-4 intruding saccades, head movement                              |
|                                          |                                       | (C) >5 intruding saccades, large head movement                          |
| Visually induced saccades                | Observation                           | (A) Normal latency, no obvious hypo- or hypermetria                     |
|                                          |                                       | (B) Long latency, dysmetria, head movement                              |
|                                          |                                       | (C) Advanced dysmetria, long latency, poor conjugation, head movement   |
| Self-paced saccades                      | Observation                           | (A) Normal intersaccadic latency, no obvious hypo- or hypermetria        |
|                                          |                                       | (B) Variable intersaccadic latency, dysmetria, head movements           |
|                                          |                                       | (C) Markedly prolonged latency, stops, closes eyes                      |
| Self-induced oscillating head movement   | Observation                           | (A) Maintains fixation, steady pace, no discomfort                     |
| Hand motion in visual field              | Observation                           | (B) Loses fixation, irregular pace, discomfort                          |
|                                          |                                       | (A) Maintains fixation, no discomfort                                   |
|                                          |                                       | (B) Fixation loss, discomfort, closes eyes                              |
| Accommodation                            | RAF near point ruler                  | Minimum expected amplitude according to the Hofstetter formula          |
| Contrast Vision                          | Pelli-Robson charts, monocular and binocular illumination 99.9 cd/m² | According to normative values                                           |

Abbreviations: OMS, ocular motor score; RAF, Royal Air Force.
Dizziness and fatigue
Twenty-eight patients (66.7%) graded symptoms of dizziness as always present. Four patients reported that symptoms were associated with head movement, and 10 patients reported motion in the environment as the cause of symptoms. The remaining 14 patients reported that symptoms were associated with both conditions. Table 5 describes the symptoms at group level. A chi-square test of independence showed no association between symptoms and CPS classification.

Before the neuro-visual examination, each patient was asked to grade their present level of fatigue using a numeric rating scale (NRS), where 0=no fatigue and 10=extreme fatigue. This was performed to get an estimate of self-perceived fatigue on the examination day. Thirty-four patients provided a rating, resulting in a mean score of 4.8 ± 2.8.

In-depth vision examination
Thirty-five patients (83.3%) had 1 or more clinical signs concerning eye teaming function, accommodative function, eye movements, or reaction to motion in the peripheral field (table 6). No associations between symptoms and CPS classification were found. The types of clinical signs are specified in table 7.

Developmental Eye Movement Test
All patients performed the Developmental Eye Movement Test. Two patients were outliers (exceeded third quartile +1.5 × IQR) and thus were excluded. There was no difference in the parameters or the ratio between patients who experienced reading issues according to the VI and patients who did not. There was no difference in the results between patients who had increased symptoms according to CISS (>21) and those who did not. A 1-way analysis of variance showed no difference in the ratio based on the CPS classification.

Symptoms vs clinical findings
A chi-square test for independence was performed to explore associations between symptoms according to the VI and clinical signs found in the vision examination. For reading difficulties (VI question 3), there was an association with a deficit in vestibular ocular reflex (VOR) head movement (Fisher exact test, \(P=0.02\)). For other visual concern (VI question 16), there was an association with eye movement deficits (Fisher exact test, \(P=0.04\)) and VOR head movement (Fisher exact test, \(P<0.01\)). Other vision concern included blurry or foggy vision, fluttery vision, a delay in visual perception, sore eyes, watching television feels different, and impaired depth perception.

Twenty-eight patients reported always experiencing at least 1 symptom related to dizziness because of head movement, motion in the environment, or a combination. In patients who had symptoms of dizziness associated with head movement, a chi-square test for independence showed associations with deficit in VOR head movement \((P=0.01)\) and deficit in eye teaming width at distance \((P=0.02)\). No

| Table 4  | Demographics |
| --- | --- |
| All Patients (N=42) | WHO CPS 4-5 (n=29) | WHO CPS 6 (n=4) | WHO CPS 7-9 (n=9) |
| Female/male, n (%) | 23/19 (54.8/45.2) | 18/11 (62.1/37.9) | 2/2 (50.0/50.0) | 3/6 (33.3/66.7) |
| Age at vision examination (y), mean ±SD | 53.4±13.3 | 51.2±14.8 | 60.9±3.1 | 57.0±8.6 |
| Time since discharge (d), median (min-max) | 162 (114-345) | 178 (114-345) | 157 (132-166) | 154 (132-308) |
| Days spent in hospital, median (min-max) | 5.0 (1-38) | 2.0 (1-20) | 15 (12-23) | 19 (15-38) |
| Abbreviations: CPS, Clinical Progression Scale; WHO, World Health Organization.

| Table 5  | Dizziness associated with head movement or motion in the environment |
| --- | --- |
| Symptom | Always | Sometimes | Never | Avoids |
| Do you become dizzy when bending over? | 5 | 21 | 16 | |
| When rolling over? | 11 | 16 | 15 | |
| When turning your head quickly? | 3 | 21 | 17 | 1 |
| If you turn your head while walking? | 9 | 16 | 17 | |
| Do you have symptoms of discomfort, unsteadiness, dizziness or imbalance when shopping in a supermarket? | 15 | 11 | 15 | 1 |
| When walking along a tree-lined street? | 6 | 4 | 32 | |
| When looking at striped or very busy patterns? | 8 | 6 | 28 | |
| When watching a movie on television or scrolling on the computer screen or tablet? | 15 | 11 | 15 | 1 |
| When people are moving around you? | 11 | 8 | 22 | 1 |
| When riding as a front seat passenger? | 8 | 8 | 24 | 1 |

NOTE. Eighteen patients responded that they always experienced at least 1 of the symptoms in association with head movement, eg, when changing posture or turning the head. Twenty-four patients responded that they always experienced at least 1 of the symptoms associated with motion in the environment.
associations were found between clinical signs and dizziness, associated with motion in the environment. Eighteen patients showed 3 or more clinical signs in the vision examination. The total number of signs in this subgroup corresponded to 76.1% of the total number of signs found. When analyzing this subgroup vs the remaining group who did the vision examination there were no significant differences in sex, number of days spent in the hospital, time since discharge from the hospital, CPS classification, or need for intensive care. However, there were differences in age (mean, 48.6±14.5 years vs 56.9±11.3 years) and fatigue according to NRS (6±2.9 vs 4.1±2.5), where the subgroup was younger (P=.04) and had higher NRS scores (P=.04).

Table 6  Number of clinical signs found in the vision examination for all included patients and patients grouped by the severity of COVID-19 at hospitalization according to the WHO CPS

| No. of Clinical Signs | All Patients (N=42) | WHO CPS 4-5 (n=29) | WHO CPS 6 (n=4) | WHO CPS 7-9 (n=9) |
|-----------------------|---------------------|--------------------|-----------------|------------------|
| None                  | 7                   | 4                  | 1               | 2                |
| 1                     | 7                   | 4                  | 1               | 2                |
| 2                     | 10                  | 7                  | 1               | 2                |
| 3                     | 4                   | 3                  | 1               | 1                |
| 4                     | 6                   | 5                  | 1               |                  |
| 5                     | 3                   | 3                  |                 |                  |
| 6                     | 2                   | 1                  |                 |                  |
| 7                     | 1                   | 1                  |                 |                  |
| 8                     | 1                   | 1                  |                 |                  |
| 9                     | 1                   | 1                  |                 |                  |

NOTE. Clinical signs are deviations in visual function, ie, where the criteria for normal function are not met. The criteria are listed in table 3, and the specific types of clinical signs found in vision examination are presented in table 7. Up to 8 clinical signs were found in a patient. CPS 4-5, hospitalized, moderate disease; CPS 6, hospitalized, severe disease, nonmechanically ventilated; CPS 7-9, hospitalized severe disease. Abbreviation: WHO, World Health Organization.

Table 7  Clinical signs found at the vision examination in all included patients

| Clinical Sign                                                                 | Patients, n (%) | Comment                             |
|-----------------------------------------------------------------------------|-----------------|-------------------------------------|
| Refractive error (n=42)                                                     | 12 (28.6)       |                                     |
| Suboptimal refractive correction                                             |                 |                                     |
| Contrast sensitivity (n=26)                                                 |                 |                                     |
| Sensitivity below expected according to age (n=42)                          | 4 (15.4)        | Cataracts (n=2)                     |
| Eye motility and versional (gaze) eye movements (n=42)                      |                 |                                     |
| Eye motility restriction                                                    | 1 (2.4)         | Premorbid condition                 |
| Fixation (saccadic intrusions, detectable drifts, or nystagmus)             | 2 (4.8)         |                                     |
| Smooth pursuit (intruding saccades or head movements)                       | 4 (9.5)         |                                     |
| Visually induced saccades (long latency, dysmetria, head movements)         | 3 (7.1)         |                                     |
| Voluntary saccade (variable or prolonged latency, dysmetria, head movements, | 12 (28.6)       |                                     |
|       stops due to discomfort)                                               |                 |                                     |
| Head movement and motion sensitivity                                         |                 |                                     |
| VOR head movement (patient-reported discomfort or observed fixation loss)   | 12 (30.8)       |                                     |
| Hand motion in peripheral visual field (patient-reported discomfort, observed | 6 (14.6)        |                                     |
|       fixation loss) (n=41)                                                  |                 |                                     |
| Binocular (eye teaming) functions (patients with stereovision, n=39)        |                 |                                     |
| Reduced fusion vergences at distance (3 m)                                  | 20 (51.3)       |                                     |
| Reduced fusion vergences at near (40 cm)                                    | 15 (38.5)       |                                     |
| Reduced near point of convergence                                           | 9 (23.1)        |                                     |
| Reduced convergence facility                                                 | 26 (66.7)       |                                     |
| Accommodative function (age <40 y, n=6)                                     |                 |                                     |
| Reduced accommodative amplitude                                             | 3 (50.0)        |                                     |

NOTE. Clinical signs are deviations in visual function, ie, where the criteria for normal function are not met. The criteria are listed in table 3. Eye motility concerns the ability to move the eyes in all directions without restriction or experiencing double vision. Versional, or gaze, eye movements are when the eyes move in unison in the same direction. The movements are stabilizing (fixation), rapid (saccades), or following (pursuit) and are essential for the acquisition of visual information, eg, through focusing, visual search and/or scanning of the environment and tracking of moving objects. Binocular functions concern the teaming of the eyes. Eye teaming is essential for maintaining clear and single (not double) vision and to adjust for different viewing distances. Eye teaming happens through vergence eye movements where the eyes move in opposite directions.
Coexisting persisting symptoms at follow-up

The results are based on telephone interview data from patients who had a clinical team examination (n=128) vs those who also had a vision examination (n=42). The results demonstrate a difference in the distribution of symptom prevalence between the groups. Patients invited to the vision examination did report symptoms affecting their daily life to a greater extent (table 8).

Discussion

Of the 433 patients interviewed 4 months after discharge from hospital, 13.9% were identified as experiencing a significant effect from at least 1 of the symptoms considered to indicate a neuro-visual dysfunction.

The symptom assessment indicated considerable percentages of remaining symptoms concerning reading, clarity of vision, headache, light and motion hypersensitivity, and dizziness affecting daily life. Difficulties with reading were frequent and associated with increased levels of eye strain. The analysis did show an association with deficits in VOR head movement, an important function for stabilizing gaze during acquisition of detailed visual information. The absence of further significant associations with clinical signs illustrates the challenges of linking a single function (visual function) to the complex process of reading.36

Blurred or doubled vision was another frequently reported symptom affecting daily life activities. There was at least 1 clinical sign in 84% of the patients, most commonly affecting eye teaming functions. The clinical signs were similar to findings in studies on patients with ABI,13-15 and further research is required to verify and understand the mechanisms.

A considerable number of the patients had suboptimal refractive correction for distance or near vision. Refractive correction is relevant not only for clear comfortable vision but also to optimize eye teaming functions. With the increased number of symptoms and signs found here and elsewhere,5,24,37 it appears that the need for proper refractive correction and/or reading aids should be considered for these patients.

Headache was reported by 47%. In patients who reported that headaches were associated with reading or near activity, obvious neuro-visual deficits and/or suboptimal correction were found. Thus, it appears that neuro-visual deficits may be part of the mechanism but given the overall constellation of symptoms, the mechanism is likely to be multifactorial.

Table 8  An analysis of the difference in rated impairments affecting daily life on body functions and activity and/or participation issues in those who were invited to a clinical team assessment (n=128) vs those who attended vision examination (n=42)

| Item                                      | n     | $\chi^2$ Value | P Value |
|-------------------------------------------|-------|----------------|---------|
| Difficulty concentrating                  | 126/42| 29.12          | <.0001  |
| Headache                                 | 126/42| 19.87          | <.0001  |
| Loud sound sensitivity (phonophobia)      | 125/42| 19.62          | <.0001  |
| Difficulty remembering                    | 126/42| 14.64          | .0001   |
| Difficulty understanding speech           | 123/41| 14.06          | .0002   |
| Stress sensitivity/irritability           | 124/39| 13.84          | .0002   |
| Mental slowness                          | 126/42| 13.71          | .0002   |
| Mental fatigue/fatigability               | 127/42| 10.46          | .0012   |
| Feeling anxious                           | 125/42| 9.31           | .0023   |
| Sleep less/disturbed sleep (>2h change)   | 123/40| 6.93           | .0085   |
| Feeling low/depressed                     | 125/41| 5.71           | .0169   |
| Weak/hoarse voice (dysphonia)             | 119/38| 3.87           | .0491   |
| Muscular soreness/aches/cramps/discomfort| 127/42| 2.96           | NS      |
| Slurred/indistinct speech (dysarthria)    | 119/38| 2.26           | NS      |
| Weakness/fatigability in arms and/or legs | 128/41| 1.76           | NS      |
| Sleep less/ disturbed sleep (>2h change)  | 125/42| 1.69           | NS      |
| Difficulty hearing                        | 125/41| 0.47           | NS      |
| Altered bodily sensation                  | 126/42| 0.26           | NS      |
| Altered smell and/or taste                | 94/30 | 0.06           | NS      |
| Difficulty swallowing                    | 112/37| 0.03           | NS      |
| Difficulty participating in social activities (socializing with friends and family)*| 122/37| 36.89| <.0001  |
| Difficulty multitasking*                  | 126/42| 29.11| <.0001  |
| Difficulty managing work/studies*         | 57/24 | 25.63| <.0001  |
| Difficulty word-finding when speaking*    | 125/41| 14.73| .0001   |
| Difficulty driving a car/using public transportation* | 111/38| 6.47| .0110   |
| Difficulty walking >1 km*                 | 125/38| 4.89           | .0270   |
| Difficulty being physically active*       | 127/42| 4.7            | .0302   |
| Difficulty managing ADL*                  | 124/39| 2.49           | NS      |
| Experienced falls after discharge*        | 127/41| 0.25           | NS      |

Abbreviations: ADL, activities of daily living; NS, not significant.
* Activity and/or participation.
Twenty-three patients (55%) reported discomfort in the eye or head when exposed to light, indicating that they had light sensitivity (photophobia). Common ocular conditions that may cause photophobia are dry eye or eye disease. Dry eye disease has been reported after COVID-19 infection. Four patients with symptoms of gritty and sore eyes, intermittent blurry vision, and light sensitivity that worsened when watching television or using a computer or mobile phone were referred for ophthalmologic assessment. Otherwise, there were no suspected signs of ocular disease in the vision examination or ocular history.

Migraine and other primary headaches are common neurologic disorders that may cause light sensitivity. The current analysis did not show any significant associations between headache and light sensitivity. However, high percentages of headache and light sensitivity have been reported in the acute phase and as part of the long-term percentages of headache and light sensitivity. Therefore, further study may be warranted to explore the association.

About two-thirds of the patients reported symptoms of dizziness. Dizziness is a neurologic manifestation associated with COVID-19 with a prevalence of 0.6%-21%. Reports describing the mechanism are scarce because of limited research involving complete vestibular evaluations. A considerable percentage of the patients reported symptoms provoked by visual motion, suggesting visual vertigo (VV). VV is defined as dizziness provoked by visual environments with large-size repetitive or moving visual patterns. Patients typically experience dizziness and discomfort in situations such as busy crowded places, in traffic, or when walking down supermarket aisles. VV may be present in patients with a history of a peripheral vestibular disorder and especially in those with high visual dependence.

A total of 83% of the patients examined had clinical signs verified with objective assessment methods. This suggests that a fairly brief battery of questions can identify patients with a potential need for intervention.

The association between fatigue and visual functions may be a subject for further study. However, the difference in the frequency of reporting cognitive impairment affecting daily life in patients with visual impairment compared with those who did not is notable. In the present study, a significant difference in self-estimated fatigue was found between patients with 3 or more clinical signs and those with 2 or less. Similar findings have been presented for patients with ABI where an association between fatigue according to the Mental Fatigue Scale and visual symptoms has been shown.

Our findings suggest that visual symptoms after COVID-19 may be associated with objective visual function issues. In a clinical setting, some of these issues could be verified through visual screening or by referring to an optometrist or other eye care specialist. Important basic interventions intended to support return to daily activities should be given in an individually adapted mix of, for example, vision therapy, proper spectacle correction, customized spectacles for reading and near activity, tinted lenses, and guidance on visual ergonomics.

**Study strengths**

The study was a cohort study and included all patients who were hospitalized because of COVID-19 infection in a health care region. All patients were interviewed according to a standardized protocol based on the International Classification of Function, Disability, and Health and included vision-related items. The study also included those who spoke a foreign language (via an interpreter).

**Study limitations**

The final sample size (N=42) is fairly small, and further research is required to verify the findings. The interview items regarding visual symptoms were chosen based on available knowledge at the time, and some symptoms may therefore not have been captured. The selection of the study group was based on self-reported symptoms. For patients with other and more troublesome symptoms, vision-related symptoms might have been neglected and thus not reported. Patients invited for a neuro-visual assessment were younger and reported a higher level of mental fatigue than those who were not invited. Younger patients might be more affected by visual dysfunctions because of a higher expected level of activity than older patients. The visual examination did not include ophthalmologic examinations, and therefore the study does not fully take ocular health into consideration. In those patients who declined participation, it is unclear if this was because of spontaneous recovery or other reasons. Neuroimaging data were not included in this study, and therefore the study does not take neurologic diagnoses into consideration. Finally, the study included only those who rated a certain level of effect or higher, and therefore underreporting is possible.

**Conclusions**

We conclude that a considerable proportion of patients (31%) with potential rehabilitation needs approximately 4 months after COVID-19 also reported vision-related symptoms. Reading-related issues, eye strain, blurry vision, and light sensitivity were the most common symptoms affecting patients’ daily life. The neuro-visual examination showed clinical signs in 83% of the patients, mainly concerning eye teaming and eye movement functions necessary to comfortably maintain clear, stable, and flexible vision. In addition, patients with vision-related symptoms reported coexisting persisting symptoms such as mental fatigue and other cognitive impairments to a greater extent than patients without vision-related symptoms, which underlines the need for future multiprofessional rehabilitation assessment and intervention.

**Suppliers**

a. SPSS Statistics 25; IBM, Armonk, NY.

b. Microsoft Excel 2010; Microsoft, Seattle, WA.

**Corresponding author**

Jan Johansson, PhD, Karolinska Institute, Department of Clinical Neuroscience, Division of Eye and Vision, St Erik Eye Hospital, Eugeniavägen 12, SE 171 64 Solna, Sweden. E-mail address: jan.johansson.1@ki.se.
References

1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–11-march-2020. Accessed July 1, 2021.

2. Korompoki E, Gavriatopoulou M, Hicklen RS, et al. Epidemiology and organ specific sequelae of post-acute COVID19: a narrative review. J Infect 2021;83:1-16.

3. Divangoglou A, Samuelsson APK, Sjodahl PE, Andersson C, Levi PR. Rehabilitation needs and mortality associated with the COVID-19 pandemic: a population-based study of all hospitalised and home-healthcare individuals in a Swedish healthcare region. EClinical Medicine 2021;36:100920.

4. Collantes MEV, Espiritu AI, Sy MCC, Anlacan VMM, Jamora RDG. Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis. Can J Neurol Sci 2021;48:66-76.

5. Javed A. Neurological associations of SARS-CoV-2 infection: a systematic review. CNS Neurol Disord Drug Targets 2022;21:246-58.

6. Maury A, Lyoubi A, Peflier-Smadja N, de Broucker T, Meppiel E. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: a narrative review for clinicians. Rev Neurol (Paris) 2021;177:51-64.

7. Romain GC, Spencer PS, Reis J, et al. The neurology of COVID-19 revisited: a proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. J Neurol Sci 2020;414:116884.

8. Tisdale AK, Dinkin M, Chwalisz BK. Afferent and efferent neuro-ophthalmic complications of coronavirus disease 19. J Neuroophthalmol 2021;41:154-65.

9. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021;27:601-15.

10. Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect 2021;27:89-95.

11. Halpin SJ, McIvor C, Whyatt G, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol 2021;93:1013-22.

12. Writing Committee for the COMEbac Study Group, Morin L, Savale L, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021;325:1525-34.

13. Berthold-Lindstedt M, Johansson J, Ygge J, Borg K. How to assess visual function in acquired brain injury—a asking is not enough. Brain Behav 2020;e01958.

14. Ciuffreda JK, Kapoor N, Rutner D, Suchoff IB, Han ME, Craig S. Occurrence of oculomotor dysfunctions in acquired brain injury: a retrospective analysis. Optometry 2007;78:155-61.

15. Rowe F, Brand D, Jackson CA, et al. Visual impairment following stroke: do stroke patients require vision assessment? Age Ageing 2009;38:188-93.

16. Berthold Lindstedt M, Johansson J, Ygge J, Borg K. Vision-related symptoms after acquired brain injury and the association with mental fatigue, anxiety and depression. J Rehabil Med 2019;51:499-505.

17. Moller MC, Johansson J, Matuseviciene G, Pansell T, Debousard CN. An observational study of trait and state fatigue, and their relation to cognitive fatigability and saccade performance. Concussion 2019;4:CNC62.

18. Jones SA, Shinton RA. Improving outcome in stroke patients with visual problems. Age Ageing 2006;35:560-5.

19. Rowe FJ. Stroke survivors’ views and experiences on impact of visual impairment. Brain Behav 2017;7:e00778.

20. Wagener SG, Kreiger R. Participation and quality of life for persons with oculomotor impairments after acquired brain injury. Br J Occup Ther 2019;82:475-8.

21. Roberts PS, Rizzo JR, Hreha K, et al. A conceptual model for vision rehabilitation. J Rehabil Res Dev 2016;6:693-704.

22. Sen M, Honavar SG, Sharma N, Sachdev MS. COVID-19 and eye: a review of opthalmic manifestations of COVID-19. Indian J Ophthalmol 2021;69:488-509.

23. Jevnikar K, Jaki Mekjavic P, Vidovic Valentinic N, Petrovski G, Globovic Petrovic M. An update on COVID-19 related ophthalmic manifestations. Ocul Immunol Inflamm 2021;29:684-9.

24. Luís ME, Hipólito-Fernandes D, Mota C, et al. A review of neuro-ophthalmological manifestations of human coronavirus infection. Eye Brain 2020;12:129-37.

25. Costa IF, Bonifáciol LP, Bellíssimo-Rodrigues F, et al. Ocular findings among patients surviving COVID-19. Sci Rep 2021;11:111085.

26. Gambini G, Savastano MC, Savastano A, et al. Ocular surface impairment after coronavirus disease 2019: a cohort study. Cornea 2021;40:477-83.

27. World Health Organization. International Classification of Functioning, Disability and Health (ICF). Available at: https://www.who.int/standards/classification/international-classification-of-functioning-disability-and-health. Accessed July 1, 2021.

28. Berthold-Lindstedt M, Ygge J, Borg K. Visual dysfunction is underestimated in patients with acquired brain injury. J Rehabil Med 2017;49:327-32.

29. Borsting EJ, Rouse MW, Mitchell GL, et al. Validity and reliability of the revised conversion insufficiency symptom survey in children aged 9 to 18 years. Optom Vis Sci 2003;12:832-8.

30. Rouse MW, Borsting EJ, Mitchell GL, et al. Validity and reliability of the revised Conversion Insufficiency Symptom Survey in adults. Ophthalmic Physiol Opt 2004;24:384-90.

31. Chang TT, Ciuffreda JK, Kapoor N. Critical flicker frequency and related symptoms in mild traumatic brain injury. Brain Inj 2007;21:1055-62.

32. Winkler PA, Ciuffreda JK. Ocular fixation, vestibular dysfunction, and visual motion hypersensitivity. Optometry 2009;80:502-12.

33. Mäntyjärvi M, Laitinen T. Normal values for the Pelli-Robson contrast sensitivity test. J Cataract Refract Surg 2001;27:326-31.

34. Olsson M, Fahnehjelm KT, Rydberg A, Ygge J. Ocular motor score a novel clinical approach to evaluating ocular motor function in children. Acta Ophthalmol 2013;91:564-70.

35. Richman JE, Garzia RP. Developmental Eye Movement Test, examiner’s booklet, version 1. Bernell Corp 1987.

36. Khateb A, Bar-Kochva I. Reading fluency-current insights from neuropsychological research and intervention studies. Cham, Switzerland: Springer International Publishing; 2016.

37. Wade DT. Rehabilitation after COVID-19: an evidence-based approach. Clin Med (Lond) 2020;4:359-65.

38. Digre KB, Brennan KC. Shedding light on photophobia. J Neuroophthalmol 2012;32:68-81.

39. Albliali A, Dilli E. Photophobia: when light hurts, a review. Curr Neurol Neurosci Rep 2018;18:62.

40. Membrilla JA, de Lorenzo I, Sastre M, Diaz de Teran J. Headache as a cardinal symptom of coronavirus disease 2019: a cross-sectional study. Headache 2020;60:2176-91.

41. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep 2021;11:16144.

42. Silva Andrade B, Siqueira S, de Assis, Soares WR, et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses 2021;13:700.

43. Fancellu V, Hatzopoulos S, Corazza V, et al. SARS-CoV-2 (COVID-19) and audio-vestibular disorders. Int J Immunopathol Pharmacol 2021;35. 20587384211027373.

44. Bronstein AM. Vision and vertigo: some visual aspects of vestibular disorders. J Neurol 2004;251:381-7.